CoChat

Multi-tiered chemical proteomic maps of tryptoline acrylamide–protein interactions in cancer cells

Open access
Njomen, Evert, Hayward, Rachel E., DeMeester, Kristen E., Ogasawara, Daisuke, Dix, Melissa M., Nguyen, Tracey, Ashby, Paige, Simon, Gabriel M., Schreiber, Stuart L., Melillo, Bruno, Cravatt, Benjamin F. · 2024 · Nature Chemistry
Cited by 53

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Covalent chemistry is a versatile approach for expanding the ligandability of the human proteome. Activity-based protein profiling (ABPP) can infer the specific residues modified by electrophilic compounds through competition with broadly reactive probes. However, the extent to which such residue-directed platforms fully assess the protein targets of electrophilic compounds in cells remains unclear. Here we evaluate a complementary protein-directed ABPP method that identifies proteins showing stereoselective reactivity with alkynylated, chiral electrophilic compounds—termed stereoprobes. Integration of protein- and cysteine-directed data from cancer cells treated with tryptoline acrylamide stereoprobes revealed generally well-correlated ligandability maps and highlighted features, such as protein size and the proteotypicity of cysteine-containing peptides, that explain gaps in each ABPP platform. In total, we identified stereoprobe binding events for >300 structurally and functionally diverse proteins, including compounds that stereoselectively and site-specifically disrupt MAD2L1BP interactions with the spindle assembly checkpoint complex leading to delayed mitotic exit in cancer cells. The ligandability of the human proteome can be expanded using covalent chemistry. A multi-tiered chemical proteomic strategy now provides in-depth maps of tryptoline acrylamide–protein interactions in cancer cells. This platform afforded the discovery of stereoselective covalent ligands for hundreds of human proteins, including compounds that disrupt protein–protein interactions regulating the cell cycle.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41557-024-01601-1

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 61

  1. Chakravarty, D. & Solit, D. B. Clinical cancer genomic profiling. Nat. Rev. Genet. 22, 483–501 (2021). · DOI · Paper page
  2. Schreiber, S. L. A chemical biology view of bioactive small molecules and a binder-based approach to connect biology to precision medicines. Isr. J. Chem. 59, 52–59 (2019). · DOI · Paper page
  3. Wang, Z. Z., Shi, X. X., Huang, G. Y., Hao, G. F. & Yang, G. F. Fragment-based drug discovery supports drugging ‘undruggable’ protein-protein interactions. Trends Biochem. Sci. 48, 539–552 (2023). · DOI
  4. St Denis, J. D., Hall, R. J., Murray, C. W., Heightman, T. D. & Rees, D. C. Fragment-based drug discovery: opportunities for organic synthesis. RSC Med. Chem. 12, 321–329 (2020). · DOI
  5. Lundquist, K. P., Panchal, V., Gotfredsen, C. H., Brenk, R. & Clausen, M. H. Fragment-based drug discovery for RNA targets. ChemMedChem 16, 2588–2603 (2021). · DOI
  6. Erlanson, D. A., Davis, B. J. & Jahnke, W. Fragment-based drug discovery: advancing fragments in the absence of crystal structures. Cell Chem. Biol. 26, 9–15 (2019). · DOI
  7. Bon, M., Bilsland, A., Bower, J. & McAulay, K. Fragment-based drug discovery-the importance of high-quality molecule libraries. Mol. Oncol. 16, 3761–3777 (2022). · DOI
  8. Wen, X., Wu, X., Jin, R. & Lu, X. Privileged heterocycles for DNA-encoded library design and hit-to-lead optimization. Eur. J. Med. Chem. 248, 115079 (2023). · DOI
  9. Shi, B., Zhou, Y., Huang, Y., Zhang, J. & Li, X. Recent advances on the encoding and selection methods of DNA-encoded chemical library. Bioorg. Med. Chem. Lett. 27, 361–369 (2017). · DOI
  10. Peterson, A. A. & Liu, D. R. Small-molecule discovery through DNA-encoded libraries. Nat. Rev. Drug Discov. 22, 699–722 (2023). · DOI · Paper page
  11. Chan, W. C., Sharifzadeh, S., Buhrlage, S. J. & Marto, J. A. Chemoproteomic methods for covalent drug discovery. Chem. Soc. Rev. 50, 8361–8381 (2021). · DOI
  12. Cuesta, A. & Taunton, J. Lysine-targeted inhibitors and chemoproteomic probes. Annu. Rev. Biochem. 88, 365–381 (2019). · DOI · Paper page
  13. Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R. & Gunning, P. T. Advances in covalent kinase inhibitors. Chem. Soc. Rev. 49, 2617–2687 (2020). · DOI · Paper page
  14. Abbasov, M. E. et al. A proteome-wide atlas of lysine-reactive chemistry. Nat. Chem. 13, 1081–1092 (2021). · DOI · Paper page
  15. Wang, C., Weerapana, E., Blewett, M. M. & Cravatt, B. F. A chemoproteomic platform to quantitatively map targets of lipid-derived electrophiles. Nat. Methods 11, 79–85 (2014). · DOI · Paper page
  16. Chen, Y. et al. Direct mapping of ligandable tyrosines and lysines in cells with chiral sulfonyl fluoride probes. Nat. Chem. 15, 1616–1625 (2023). · DOI
  17. Weerapana, E. et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468, 790–795 (2010). · DOI · Paper page
  18. Gygi, S. P. et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994–999 (1999). · DOI · Paper page
  19. Kuljanin, M. et al. Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries. Nat. Biotechnol. 39, 630–641 (2021). · DOI · Paper page
  20. Grossman, E. A. et al. Covalent ligand discovery against druggable hotspots targeted by anti-cancer natural products. Cell Chem. Biol. 24, 1368–1376.e4 (2017). · DOI · Paper page
  21. Lazear, M. R. et al. Proteomic discovery of chemical probes that perturb protein complexes in human cells. Mol. Cell 83, 1725–1742 (2023). · DOI
  22. Tao, Y. et al. Targeted protein degradation by electrophilic PROTACs that stereoselectively and site-specifically engage DCAF1. J. Am. Chem. Soc. 144, 18688–18699 (2022). · DOI · Paper page
  23. Feldman, H. C. et al. Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domain. Proc. Natl Acad. Sci. USA 119, e2208457119 (2022). · DOI · Paper page
  24. Kathman, S. G. et al. Remodeling oncogenic transcriptomes by small molecules targeting NONO. Nat. Chem. Biol. 19, 825–836 (2023). · DOI
  25. Kavanagh, M. E. et al. Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine. Nat. Chem. Biol. 18, 1388–1398 (2022). · DOI
  26. Darabedian, N. et al. Depletion of creatine phosphagen energetics with a covalent creatine kinase inhibitor. Nat. Chem. Biol. 19, 815–824 (2023). · DOI
  27. Gao, Z., Chang, C., Yang, J., Zhu, Y. & Fu, Y. AP3: an advanced proteotypic peptide predictor for targeted proteomics by incorporating peptide digestibility. Anal. Chem. 91, 8705–8711 (2019). · DOI
  28. Lanning, B. R. et al. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nat. Chem. Biol. 10, 760–767 (2014). · DOI · Paper page
  29. Niessen, S. et al. Proteome-wide map of targets of T790M-EGFR-directed covalent inhibitors. Cell Chem. Biol. 24, 1388–1400 (2017). · DOI
  30. Warren, A. et al. Global computational alignment of tumor and cell line transcriptional profiles. Nat. Commun. 12, 22 (2021). · DOI · Paper page
  31. Rostovtsev, V. V., Green, L. G., Fokin, V. V. & Sharpless, K. B. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective ‘ligation’ of azides and terminal alkynes. Angew. Chem. Int. Ed. 41, 2596–2599 (2002). · DOI · Paper page
  32. Tornoe, C. W., Christensen, C. & Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 67, 3057–3064 (2002). · DOI · Paper page
  33. Speers, A. E., Adam, G. C. & Cravatt, B. F. Activity-based protein profiling in vivo using a copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J. Am. Chem. Soc. 125, 4686–4687 (2003). · DOI · Paper page
  34. Teng, M., Zhou, S., Cai, C., Lupien, M. & He, H. H. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein Cell 12, 29–38 (2021). · DOI · Paper page
  35. Vinogradova, E. V. & Cravatt, B. F. Multiplexed proteomic profiling of cysteine reactivity and ligandability in human T cells. STAR Protoc. 2, 100458 (2021). · DOI
  36. Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564–576 (2017). · DOI · Paper page
  37. Serrano, G., Guruceaga, E. & Segura, V. DeepMSPeptide: peptide detectability prediction using deep learning. Bioinformatics 36, 1279–1280 (2020). · DOI
  38. Li, H. et al. Assigning functionality to cysteines by base editing of cancer dependency genes. Nat. Chem. Biol. 19, 1320–1330 (2023). · DOI · Paper page
  39. Taylor, C. A. T. et al. Domain-swapping switch point in Ste20 protein kinase SPAK. Biochemistry 54, 5063–5071 (2015). · DOI
  40. Tan, L., Yu, J. T. & Tan, L. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J. Neurol. Sci. 323, 1–8 (2012). · DOI · Paper page
  41. Dewulf, J. P. et al. Urine metabolomics links dysregulation of the tryptophan-kynurenine pathway to inflammation and severity of COVID-19. Sci. Rep. 12, 9959 (2022). · DOI
  42. Thomas, T. et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight 5, e140327 (2020). · DOI · Paper page
  43. Hu, L. J. et al. A simple HPLC-MS/MS method for determination of tryptophan, kynurenine and kynurenic acid in human serum and its potential for monitoring antidepressant therapy. J. Anal. Toxicol. 41, 37–44 (2017). · DOI
  44. Dobrovolsky, V. N. et al. Effect of arylformamidase (kynurenine formamidase) gene inactivation in mice on enzymatic activity, kynurenine pathway metabolites and phenotype. Biochim. Biophys. Acta 1724, 163–172 (2005). · DOI
  45. Bachovchin, D. A. et al. Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening. Proc. Natl Acad. Sci. USA 107, 20941–20946 (2010). · DOI · Paper page
  46. Westhorpe, F. G., Tighe, A., Lara-Gonzalez, P. & Taylor, S. S. p31comet-mediated extraction of Mad2 from the MCC promotes efficient mitotic exit. J. Cell Sci. 124, 3905–3916 (2011). · DOI
  47. Hagan, R. S. et al. p31comet acts to ensure timely spindle checkpoint silencing subsequent to kinetochore attachment. Mol. Biol. Cell 22, 4236–4246 (2011). · DOI
  48. Lok, T. M. et al. Mitotic slippage is determined by p31comet and the weakening of the spindle-assembly checkpoint. Oncogene 39, 2819–2834 (2020). · DOI
  49. Yang, M. et al. p31comet blocks Mad2 activation through structural mimicry. Cell 131, 744–755 (2007). · DOI · Paper page
  50. Abdel-Salam, G. M. H. et al. Biallelic MAD2L1BP (p31comet) mutation is associated with mosaic aneuploidy and juvenile granulosa cell tumors. JCI Insight 8, e170079 (2023). · DOI
  51. Browne, C. M. et al. A chemoproteomic strategy for direct and proteome-wide covalent inhibitor target-site identification. J. Am. Chem. Soc. 141, 191–203 (2019). · DOI · Paper page
  52. Wozniak, J. M. et al. Enhanced mapping of small-molecule binding sites in cells. Nat. Chem. Biol. 20, 823–834 (2024). · DOI
  53. Mons, E., Kim, R. Q. & Mulder, M. P. C. Technologies for direct detection of covalent protein–drug adducts. Pharmaceuticals 16, 547 (2023). · DOI
  54. Giansanti, P., Tsiatsiani, L., Low, T. Y. & Heck, A. J. Six alternative proteases for mass spectrometry-based proteomics beyond trypsin. Nat. Protoc. 11, 993–1006 (2016). · DOI · Paper page
  55. Abegg, D. et al. Chemoproteomic profiling by cysteine fluoroalkylation reveals myrocin G as an inhibitor of the nonhomologous end joining DNA repair pathway. J. Am. Chem. Soc. 143, 20332–20342 (2021). · DOI
  56. Tessier, R. et al. Ethynylation of cysteine residues: from peptides to proteins in vitro and in living cells. Angew. Chem. Int. Ed. 59, 10961–10970 (2020). · DOI · Paper page
  57. Motiwala, H. F., Kuo, Y. H., Stinger, B. L., Palfey, B. A. & Martin, B. R. Tunable heteroaromatic sulfones enhance in-cell cysteine profiling. J. Am. Chem. Soc. 142, 1801–1810 (2020). · DOI · Paper page
  58. Cuesta, A., Wan, X., Burlingame, A. L. & Taunton, J. Ligand conformational bias drives enantioselective modification of a surface-exposed lysine on Hsp90. J. Am. Chem. Soc. 142, 3392–3400 (2020). · DOI · Paper page
  59. Jacobs, A. T. & Marnett, L. J. Systems analysis of protein modification and cellular responses induced by electrophile stress. Acc. Chem. Res. 43, 673–683 (2010). · DOI · Paper page
  60. Békés, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022). · DOI · Paper page
  61. Zhang, Y. et al. Expanding the ligandable proteome by paralog hopping with covalent probes. Preprint at bioRxiv https://doi.org/10.1101/2024.01.18.576274 (2024). · DOI

Cited by

See all 53

Metadata

Authors
Njomen, E., Hayward, R. E., DeMeester, K. E., Ogasawara, D., Dix, M. M., Nguyen, T., Ashby, P., Simon, G. M., Schreiber, S. L., Melillo, B., & Cravatt, B. F.
Venue
Nature Chemistry
Published
2024-08-13
Volume
16
Issue
10
Pages
1592-1604
ISSN
  • 1755-4330 (ISSN-L)
  • 1755-4349
OpenAlex
W4401548057
Cited by
53
References
21
FWCI
7.25
Type
journal article
Language
en
Open access
green
Licence
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19 AI142784)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA231991, OT2 CA278692)
  • Cancer Research UK (CGCATF-2021/100021)
  • Howard Hughes Medical Institute (GT15176)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multi-tiered chemical proteomic maps of tryptoline acrylamide–protein interactions in cancer cells. https://app.cochat.ai/papers/10.1038/s41557-024-01601-1
The paper
Njomen, E., Hayward, R. E., DeMeester, K. E., Ogasawara, D., Dix, M. M., Nguyen, T., Ashby, P., Simon, G. M., Schreiber, S. L., Melillo, B., & Cravatt, B. F. (2024). Multi-tiered chemical proteomic maps of tryptoline acrylamide–protein interactions in cancer cells. Nature Chemistry. https://doi.org/10.1038/s41557-024-01601-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.